Gralow, MD, FACP, FASCO, chief medical officer and executive vice president of ASCO, said, People with [IBD], including Crohns disease and ulcerative colitis, are known to have higher risk of developing colorectal cancer
PlexusDx's precision-wellness approach helps contextualize how genetic predispositions in peptide pathways may inform conversations with providers about optimal treatment strategies
S.YuenM
Clinical trials show dual-pathway activation produces greater weight loss than single-pathway therapy, without requiring separate lipotropic injections
These are trait-level tendencies, not verdicts on any product
As the World Health Organization recently issued guidance supporting the use of GLP-1 medications in obesity care, these drugs reached a new milestone